Vaccines made in Africa for Global Health
VaxSen is a subsidiary of Institut Pasteur de Dakar (IPD) dedicated to manufacturing and commercialization of vaccines.
IPD, a world-renowned public health institution with more than a 100-year legacy – has been a pioneer in infectious disease control and vaccine production.
Today, VaxSen builds on this heritage, advancing Africa’s goal of producing 60% of its vaccines by 2040.
We produce high-quality, life-saving vaccines, ensuring equitable access and reinforcing the continent’s health sovereignty.
Our Core Pillars
VaxSen is leading a new era of health resilience in Africa. Our vision is built on three core pillars that guide our work, our partnerships, and our impact.
- A New Standard for Health Sovereignty
We are committed to strengthening Africa’s readiness to respond to outbreaks and future health threats by providing a local, sustainable source of essential vaccines. Our work ensures that communities across the continent are protected, no matter the challenge.
- Our Production
Our state-of-the-art MADIBA facility is designed to meet and exceed global standards, producing up to 300 million vaccine doses annually. We leverage cutting-edge technologies and a robust supply chain to ensure that high-quality, safe, and effective vaccines are always available.
- Our Network
Our mission is powered by strong strategic partnerships. We collaborate with governments, international institutions, and leading organizations to drive sustainable health, economic, and social value across Africa. Our network is our strength.
Stay Informed
Stay up-to-date with our latest announcements, press releases, and insights. This is where we share our journey as a key player in Africa’s health security, from our manufacturing milestones to our strategic partnerships.
Our History
A legacy of excellence
A new era of innovation
Since its founding in 1896, the Institut Pasteur de Dakar (IPD) has stood at the forefront of Africa’s fight against infectious diseases.
As the continent’s first microbiology laboratory and a reference for global public health, IPD has built a distinguished legacy of scientific excellence.
The institution’s expertise was recognized internationally as early as 1937, when it became the first WHO-prequalified vaccine manufacturer in Africa.
With the strategic objective of expanding Africa’s manufacturing capacity, IPD launched MADIBA (Manufacturing in Africa for Disease Immunization and Building Autonomy) in 2021. This initiative, with significant support from the Senegalese government and international partners, created a cutting-edge facility with the capacity to produce 300 million vaccine doses annually.
The creation of VaxSen marks a turning point, to lead the production and commercialization of these life-saving vaccines.
Established as a fully owned commercial subsidiary of IPD, VaxSen is the embodiment of our history: it carries forward IPD’s legacy of excellence, turning decades of scientific heritage into a bold, forward-looking solution for Africa’s health security.
Our Vision
A Bold New Chapter in African Health Security.
VaxSen aims to fill a critical gap: building sustainable, locally rooted vaccine production that is fit for the future. We believe that Africa must have the tools and resources to safeguard its own health security. Our vision is to lead a new era where the continent’s population has equitable and affordable access to life-saving vaccines, ensuring resilience against both current and future health threats.
Our work is driven by a clear set of values:
Equity
Ensuring life-saving vaccines reach every community.
Resilience
Strengthening Africa’s readiness to respond to outbreaks.
Collaboration
Partnering with governments, donors, and industry for collective progress.
Sustainability
Creating lasting health, economic, and environmental benefits.
Our Impact
Manufacturing vaccines for a Healthier Africa
VaxSen is more than a manufacturer; we are a catalyst for change. Our commitment to Africa’s health sovereignty is delivered through tangible actions that have a lasting impact.
1
Delivering
at Scale
We produce up to 300 million vaccine doses annually from our state-of-the-art MADIBA facility, ensuring a reliable supply for both routine immunization and rapid emergency response across the continent.
2
Creating Local
Opportunity
We support local economies by creating jobs, developing world-class biomanufacturing talent, and boosting regional supply chains.
3
Strengthening
Health Security
By building a sustainable production ecosystem, we empower Africa with the tools and resources to safeguard its future health and economic stability.
Leadership
VaxSen’s mission is championed by a leadership team deeply committed to public health and African development. Our governance structure reflects a perfect balance of scientific rigor, financial stewardship, and mission-driven purpose, drawing from leaders across government, academia, and global health.
Our Board
Our Board provides strategic oversight, drawing from a wealth of experience across government, academia, and global health. Their collective expertise ensures our governance reflects the highest standards of scientific rigor and financial stewardship.
Dr. Ibrahima Soce Fall
Board Chair and Director General of IPD
A 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐂𝐨𝐥𝐨𝐧𝐞𝐥 𝐚𝐧𝐝 𝐢𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥𝐥𝐲 𝐫𝐞𝐧𝐨𝐰𝐧𝐞𝐝 𝐞𝐩𝐢𝐝𝐞𝐦𝐢𝐨𝐥𝐨𝐠𝐢𝐬𝐭, Dr. Fall is a seasoned expert in public health, emergency response, and health diplomacy. Prior to his appointment as DG he served as Assistant Director-General for Emergency Response at...
Dr. Ibrahima Soce Fall
A 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐂𝐨𝐥𝐨𝐧𝐞𝐥 𝐚𝐧𝐝 𝐢𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥𝐥𝐲 𝐫𝐞𝐧𝐨𝐰𝐧𝐞𝐝 𝐞𝐩𝐢𝐝𝐞𝐦𝐢𝐨𝐥𝐨𝐠𝐢𝐬𝐭, Dr. Fall is a seasoned expert in public health, emergency response, and health diplomacy. Prior to his appointment as DG he served as Assistant Director-General for Emergency Response at the World Health Organization (WHO), where he played a key role in coordinating global responses to major epidemics.
Born in Dakar and holding degrees in medicine, public health, and epidemiology, Dr. Fall has dedicated his career to combating infectious diseases, strengthening health systems, and enhancing pandemic preparedness, with field 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐢𝐧 𝐨𝐯𝐞𝐫 𝟓𝟎 𝐜𝐨𝐮𝐧𝐭𝐫𝐢𝐞𝐬.
His returned to Senegal to lead the IPD in June 2025 and this marks a new chapter in the institution’s history. His expertise, strategic vision, and commitment to African health sovereignty will be major assets in continuing the momentum of innovation, research, and local production.
Dr. El Hadji Mamadou Ndiaye
Dr. El Hadji Mamadou Ndiaye is a distinguished Senegalese physician...
Dr. El Hadji Mamadou Ndiaye
Dr. El Hadji Mamadou Ndiaye is a distinguished Senegalese physician specializing in public health and vaccinology. As the Director of Prevention at Senegal’s Ministry of Health and Social Action, he has been instrumental in advancing national immunization initiatives, including the Expanded Program on Immunization (EPI). His leadership has been pivotal in combating diseases such as polio and cervical cancer through effective vaccination campaigns. Dr. Ndiaye’s expertise is further recognized by his designation as a Chevalier of the National Order of the Lion, underscoring his significant contributions to public health in the region
Prof. Yasmine Belkaid
Professor Yasmine Belkaid is a world-renowned immunologist and the President...
Prof. Yasmine Belkaid
Professor Yasmine Belkaid is a world-renowned immunologist and the President of the Institut Pasteur Paris, where she drives groundbreaking research in global health and microbiome science. With a PhD in immunology from Paris-Sud University and over 220 published studies, her pioneering work on host-microbe interactions has earned her prestigious accolades, including the Robert Koch Prize and the Lurie Prize in Biomedical Sciences. A visionary leader, Professor Belkaid combines scientific excellence with a commitment to advancing health innovation and equity worldwide.
M. Amadou Birahim GUEYE
Amadou Birahim Gueye is the Principal Treasury Inspector and Technical...
M. Amadou Birahim GUEYE
Amadou Birahim Gueye is the Principal Treasury Inspector and Technical Advisor to the Minister of Finance and Budget since March 2025.
With 20 years of experience at the General Directorate of Public Accounting and the Treasury, he has held
several key positions. These include Director of the Parapublic Sector, where he managed the State’s portfolio, and Director of Public Accounting, where he spent three years developing the State’s financial and accounting regulations.
Mr. Gueye holds a master’s degree in private law (specializing in business law) and is an alumnus of
Senegal’s National School of Administration (ENA), graduating in 2001-2003. He also holds a diploma from the ENA’s International Short Course in France. In addition to his primary duties, he serves as a director on the boards of several public companies and foundations, including the Pasteur Institute Foundation in Dakar and the Amadou Mahtar Mbow Foundation.
He also lectures on public finance and public accounting at Senegal’s National School of Administration (ENA) and various other training institutes.
Prof. Awa Marie Coll Seck
Professor Awa Marie Coll-Seck is a renowned physician and public...
Prof. Awa Marie Coll Seck
Professor Awa Marie Coll-Seck is a renowned physician and public health advocate with decades of leadership in global health and infectious disease control. A former Senegalese Minister of Health, she also served as Executive Director of the Roll Back Malaria Partnership and Director at UNAIDS, shaping global policies on HIV/AIDS and malaria. With over 150 scientific publications and numerous international honors, Professor Coll-Seck continues to drive transformative health initiatives and champion equity in healthcare worldwide.
Cheikh Tidiane Mbaye
Cheikh Tidiane Mbaye is a distinguished Senegalese telecommunications executive renowned...
Cheikh Tidiane Mbaye
Cheikh Tidiane Mbaye is a distinguished Senegalese telecommunications executive renowned for his transformative leadership in the industry. Serving as CEO of Sonatel, Senegal’s leading telecommunications provider, from 1988 to 2012, he was instrumental in expanding the company’s services across West Africa. Beyond his corporate achievements, Mbaye has demonstrated a strong commitment to education, particularly in enhancing access for girls, through his role as Chairman of Fondation Sonatel. He also chairs the Board of Directors at AIMS Senegal, reflecting his dedication to advancing mathematical sciences on the continent.
James Robinson
James Robinson is an accomplished consultant and specialist in vaccine...
James Robinson
James Robinson is an accomplished consultant and specialist in vaccine manufacturing and development, with a focus on addressing endemic and pandemic diseases in developing markets. An advisor to the Institut Pasteur de Dakar since 2017, Jim has held leadership roles at Merck, Novavax, and Sanofi Pasteur, where he contributed to the production of nearly 2 billion vaccine doses, including those for influenza, MMR, HPV, and Ebola.
With a BS and MS in Chemical Engineering from Lehigh University and extensive expertise in scaling vaccine production, Jim has driven innovation in manufacturing technologies to expand access and reduce costs. As Vice-Chair of CEPI’s Scientific Advisory Committee, he shaped global COVID-19 response strategies and continues to support key health initiatives through CEPI, the Gates Foundation, and PATH.
François Edmond G. Romaneix
François Romaneix is a distinguished administrator and financial strategist, serving...
François Edmond G. Romaneix
François Romaneix is a distinguished administrator and financial strategist, serving as the Senior Executive Vice-President of Administration and Finance at the Institut Pasteur since April 2017. He has held pivotal roles in both governmental and healthcare sectors. His career includes significant positions such as Director of the Office of the French Minister of Civil Service and Deputy Director at the Ministry of Culture.
Our CEO
Assietou Sylla Diouf – CEO, VaxSen
Assietou Diouf serves as the inaugural Chief Executive Officer of VaxSen, a wholly owned subsidiary of Institut Pasteur of Dakar, leading the commercialisation of vaccines across Africa and globally. A...
Assietou Sylla Diouf – CEO, VaxSen
Assietou Diouf serves as the inaugural Chief Executive Officer of VaxSen, a wholly owned subsidiary of Institut Pasteur of Dakar, leading the commercialisation of vaccines across Africa and globally.
A seasoned executive, Assietou brings to VaxSen a diverse international experience with public and private organisations as well as expertise in financial governance, global health, transformation and risks management.
Previously, Ms Diouf was Chief Financial Officer of Gavi, the Vaccine Alliance, where she played a pivotal role in championing vaccine accessibility. Before joining Gavi, she was Director of Programming, Budgeting, Finance and Accounting at the African Union, where she advised senior leadership on financial strategies and led the financial component of the African Union’s budgetary and financial management reforms.
Ms Diouf’s private-sector experience spans senior roles at several leading financial institutions in Senegal, the UK and the UAE. She is a Trustee of IFRS Foundation and a member of several not for profit organisations (Integrate Health, International Financial Reporting for Non-Profit Organisations -IFR4NPO).
Ms Diouf is a qualified chartered accountant (France). She received a Master’s degree in Finance and Business Administration from Sup de Co Amiens in France and holds certifications in Authentic Leadership from Harvard and in Corporate Strategy from the Balanced Scorecard Institute.
Today, she leads the charge to redefine vaccine manufacturing in Africa. At VaxSen, she spearheads efforts to forge strategic collaborations, drives regional regulatory harmonization, and fosters innovation, ensuring VaxSen delivers on its promise to build Africa’s health sovereignty. Under Assietou’s guidance, VaxSen is not just manufacturing vaccines—it is manufacturing hope for a healthier, more resilient Africa.
Production
The MADIBA facility is strategically located, between the airport and the capital, in the industrial hub of Diamniadio, Senegal.
This state-of-the-art hub for vaccine manufacturing is designed to address Africa’s critical need for vaccine self-reliance. This flagship facility will ensure a sustainable supply of life-saving vaccines for the continent.
With a target capacity of over 300 million doses per year, MADIBA is a multi-product facility equipped to produce various types of vaccines, including live viral vaccines, mRNA vaccines, and protein-subunit vaccines. By handling both full production and filling, we provide a complete, end-to-end solution for a more secure and resilient Africa.
Our Product Portfolio
Our long-term vision is to build a robust portfolio of regionally relevant vaccines. Our initial focus includes expanding our offerings to cover Measles/Rubella, Polio, and rotavirus. We are also committed to developing a cell-culture yellow fever candidate.
As the preferred CEPI manufacturer in Africa, we will begin production of the Lassa Fever vaccine candidate. This key partnership reinforces our role as a trusted partner in global health security, ready to respond to emerging threats.
Partnerships
We're proud to have the backing of the Government of Senegal and a wide coalition of international partners and philanthropic donors, whose support is essential to our success. Together, we are building a new model for vaccine manufacturing that is rooted in Africa and ready to serve the world.
Building a Network for
Global Health
At VaxSen, we believe that tackling global health challenges requires collective action. Our success is built on a foundation of strong, strategic partnerships with organizations that share our commitment to health equity and self-reliance.
We are always looking to forge new partnerships with organizations that share our vision. Let’s work together to build a healthier, more resilient Africa.
Our Partners
We are proud to work with a diverse network of collaborators who provide the essential support needed to make our mission a reality.
- Strategic & Institutional Partners
These collaborations with governments, international organizations, and key public health bodies are fundamental to strengthening Africa’s health security.
- Financial & Philanthropic Partners
Our work is made possible through the generous support of foundations and financial institutions who believe in the importance of local vaccine production.
- Scientific & Technical Partners
We partner with leading research institutions and industry leaders to advance our capabilities and expand our vaccine portfolio.





News
Stay up to date on our mission
This is where VaxSen’s story unfolds. From the groundbreaking work at our MADIBA facility to our strategic collaborations and milestones in African health sovereignty, this section is your source for the latest updates.
Here, you will find our official press releases, news articles, and insights into our role as a key player in vaccine manufacturing and global health.








A Decisive Step for African Vaccine Sovereignty!
On December 13, 2024, VaxSen secured $45 million in strategic funding from the AfDB, IFC, and DFC. This agreement, signed in the presence of President Bassirou Diomaye Faye, confirms Senegal’s position as a production hub in Africa. This tripartite financing is the
Careers
Join our team: a purpose-driven career
Why Join VaxSen ?
At VaxSen, we don’t just offer jobs—we offer a chance to be part of a mission that’s redefining the future of health in Africa.
We are looking for passionate professionals dedicated to scientific excellence, innovation, and global health equity.
If you are an expert in biomanufacturing, quality assurance, research, or business, and you are ready to make a tangible impact, join our team.
Working with VaxSen means :
- Becoming part of a unique ecosystem where the scientific legacy of excellence from the Institut Pasteur de Dakar meets a bold vision for the future of health in Africa.
- Contributing to Africa's health sovereignty by partnering with a world-class production facility.